A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

NCT01970137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Spinocerebellar Degeneration

Interventions

DRUG: KPS-0373, High dose
DRUG: KPS-0373, Low dose

Sponsor

Kissei Pharmaceutical Co., Ltd.